Targeted therapy for leptomeningeal metastases in non-small cell lung cancer – Changing treatment paradigms

Binay Kumar Shah^{1,2,3}, Isaac Pak³, Nibash Budhathoki⁴, Kayla Buker⁵

¹Binaytara Foundation, Bellingham, WA 98226, USA; ²Cancer Center, PeaceHealth United General Hospital, Sedro Woolley, WA 98284, USA;

³Pacific Northwest University School of Medicine, Yakima, WA 98901, USA; ⁴Department of Internal Medicine, Interfaith Medical Center,

Brooklyn, NY 11213, USA; ⁵Creighton University School of Medicine, Omaha, Nebraska 68178, USA

Correspondence to: Dr. Binay Kumar Shah. PeaceHealth United General Hospital, 2000 Hospital Drive, Sedro-Woolley, WA 98284, USA. Email: binay.s@binayfoundation.org.

Abstract

Leptomeningeal metastasis is an uncommon but serious complication in patients with advanced cancers. Leptomeningeal metastasis is diagnosed in approximately 5% of the patients, most commonly among patients with cancers of breast and lung, melanoma, and gastrointestinal malignancies. Treatment goal is to improve survival and quality of the patients. Use of targeted therapies and immunotherapy has led to improved survival of patients with non-small cell lung cancer (NSCLC). In this article, we review emerging data on use of mutation-specific agents and immunotherapy in the treatment of leptomeningeal metastasis among patients with NSCLC.

Keywords: Non-small cell lung cancer; leptomeningeal metastases; immunotherapy

Submitted Sep 26, 2017. Accepted for publication Dec 16, 2017.

doi: 10.21147/j.issn.1000-9604.2017.06.08

View this article at: <https://doi.org/10.21147/j.issn.1000-9604.2017.06.08>

Introduction

Leptomeningeal metastasis, or leptomeningeal carcinomatosis, is a rare, but often devastating complication arising from the seeding of malignant cells from advanced stage cancers to the leptomeninges. While autopsy studies have confirmed the presence of these metastases in approximately 20% of patients with metastatic cancer, leptomeningeal metastases are currently only diagnosed in about 5% of living patients with existing metastatic disease, most notably cancers of the breast and lung, melanoma, and gastrointestinal malignancies (1). This suggests that patients may have non-specific symptoms until the disease has progressed to a late stage, making a high index of clinical suspicion crucial in early diagnosis and successful treatment. This is especially pertinent due to the rising incidence of this complication, most likely associated with increased survival time with improved treatment protocols (1).

Leptomeningeal metastases involve tumors of the inner

layers of the meninges and the subarachnoid space, in which the cerebrospinal fluid (CSF) circulates. They can be categorized into two types: diffuse type, which involves non-adherent cells without contrast-enhancing nodular lesions in subarachnoid space; or nodular type, characterized by contrast-enhancing leptomeningeal tumor nodules (2). Identifying the differences between these types may help guide treatment methods.

Treatment goals are also specific to the location and severity of metastasis. Primary treatment goals include both prolonged survival and symptomatic relief from neurological involvement, as well as restoration of satisfactory quality of life. Stratifying patients into risk categories based on parameters such as Karnofsky performance status, neurological deficits, and extent of systemic disease can be helpful in driving treatment course. In severe cases, palliative care is favored over aggressive treatment. There is currently no standard of treatment due to the limited data in the literature secondary to rapid progression and relative rarity of the disease.

In patients with non-small cell lung cancer (NSCLC), the incidence of leptomeningeal metastasis is approximately 3.8%, with about a third of these patients having concomitant brain metastases (3). The median overall survival for these patients is between 3.6 to 11.0 months, using modern treatment modalities (3). One of the challenges of chemotherapy is adequate penetration of the blood-brain barrier into the central nervous system (CNS). This may explain why traditional chemotherapy is often ineffective in patients with CNS metastases. Identifying NSCLC patients with specific driver mutations, which are currently found in about 20%–25% of these patients, allows for treatment with targeted therapies tailored toward their mutation, which could increase efficacy. These therapies may also be used in patients where traditional chemotherapy is not an option. The most common mutations seen are *KRAS* mutation (29%), epidermal growth factor receptor (*EGFR*) mutation (11%), anaplastic lymphoma kinase (*ALK*) rearrangement (5%), and *MET* mutation (4%) (4). We will discuss some of these mutations in NSCLC patients with leptomeningeal metastases and provide an overview of emerging advancements in mutation-specific therapies.

EGFR mutations

EGFR mutations are a dominant subtype of NSCLC and account for about 10% of lung cancers in the Caucasian population and up to 50% in the Asian population, with an average survival of 3.1 months (5). The incidence of leptomeningeal metastases in *EGFR*-mutant NSCLC is significantly higher than *EGFR*-wild-type NSCLC (9.4% vs. 1.7%, $P < 0.001$) (5). *EGFR* tyrosine kinase inhibitors (TKIs) are the standard of care in this population as they have improved response rates and superior progression-free survival (PFS) and quality of life to traditional chemotherapy (6). One of the advantages of *EGFR*-TKIs is their superior CSF penetration compared to traditional systemic chemotherapeutic agents. Their efficacy is proven by retrospective studies which show an average improvement in overall survival of 19 months (5).

First-generation *EGFR*-TKIs, erlotinib and gefitinib, are currently used as first-line treatments. Both drugs have similar toxicity profiles, but there may be some differences in terms of efficacy (7). Several studies have disease control with erlotinib following progression of disease on gefitinib (8–10). Erlotinib has also been shown to have better CSF penetration and higher concentrations in the CSF (11).

Togashi *et al.* examined 15 patients and found that CSF concentration and penetration ($\bar{x} \pm s$) of erlotinib were 28.7 ± 16.8 ng/mL and $2.77\% \pm 0.45\%$, compared to gefitinib, which had a CSF concentration and penetration of only 3.7 ± 1.9 ng/mL and $1.13\% \pm 0.36\%$ (12). A retrospective review of 25 patients with leptomeningeal metastases and *EGFR*-positive NSCLC also found that erlotinib was more effective in clearing malignant cells from the CSF than gefitinib (13). These data suggest that erlotinib may have better control of leptomeningeal metastases in *EGFR*-positive NSCLC than gefitinib.

There are several mechanisms that lead to acquired resistance to *EGFR*-TKIs, including T790M mutation and c-Met amplification (5). These changes are seen in over 50% of patients after first-generation TKI failure (5). Newer generations of *EGFR*-TKIs have been devised that are effective in NSCLC patients who have developed resistance to first-generation *EGFR*-TKIs. Afatinib is a second-generation *EGFR*-TKI that has shown superior CNS response and has been shown to be effective even after TKI failure (14).

This was shown by Hoffknecht *et al.*, who examined 541 patients in the afatinib compassionate use program. There are scant data in the established literature about the penetration rates of afatinib, but Hoffknecht *et al.* reported that the CSF-to-plasma ratio was 0.69% in one patient (14). The data, however, indicate that despite the lower ratio, afatinib achieves concentrations high enough to have a clinical effect.

Osimertinib is a third-generation *EGFR*-TKI that has been approved by the Food and Drug Administration (FDA) for use in patients with *EGFR* T790M mutation (15). The collective evidence suggests that osimertinib has higher efficacy and penetration than first-generation *EGFR*-TKIs. For example, in preclinical trials, Ballard *et al.* demonstrated that the distribution of osimertinib was approximately 10-fold higher than gefitinib (16) and Nanjo *et al.* demonstrated five times higher CSF efficacy than erlotinib (17). Phase I and II BLOOM trials have also shown its efficacy, measured by radiological improvement and control of leptomeningeal metastases (18). Phase III (AURA3) studied 419 patients with *EGFR*-mutant NSCLC who had progression of disease with first-line therapy. In these patients, treatment with osimertinib had significantly greater efficacy than traditional chemotherapy, including longer median PFS (10.1 months vs. 4.4 months, $P < 0.001$), and higher objective response rates, 71% in osimertinib group [95% confidence interval (95% CI), 65%–76%] and

31% in the platinum-pemetrexed group (95% CI, 24%–40%), with lower incidence of adverse effects leading to permanent discontinuation (19). Furthermore, this study also examined CNS metastases and demonstrated that osimertinib had better results than platinum-pemetrexed. The hazard ratio for PFS also favored osimertinib specifically in patients with CNS metastases (median PFS: 8.5 months vs. 4.2 months, with a hazard ratio of 0.32; 95% CI, 0.21–0.49) (19). These results are particularly encouraging in NSCLC patients with suspected or diagnosed leptomeningeal metastases.

Combination therapy with EGFR-TKIs and bevacizumab, which is directed at vascular endothelial growth factor A (VEGF-A) also used in NSCLC, has also been shown to be effective in patients who have failed monotherapy with erlotinib alone. Ariyasu *et al.* found that the combination of erlotinib and bevacizumab showed improved efficacy in two case studies, including decreased radiographic activity and improved symptom control (20). Sakata *et al.* found similar improved performance status and CSF penetration in one patient treated with this same combination. In this patient, CSF penetration of erlotinib was found to be 5.4%, much higher than the reported average CSF penetration of $1.13\% \pm 0.36\%$ with erlotinib alone (12,21). Furugaki *et al.* also found improvement in anti-tumor activity with the combination of bevacizumab to erlotinib, but only in the subset of patients with c-Met amplification and only in those who were already sensitive to erlotinib alone (22). Combinations with gefitinib and bevacizumab have also been shown to be well-tolerated and effective. In a single-arm phase II trial in treatment-naïve patients, Ichihara *et al.* showed that this combination therapy had improved PFS and tolerable toxicity (23). Yet another trial is currently ongoing, examining osimertinib and bevacizumab for EGFR-mutant NSCLC (NCT02803203). These preliminary data show that combination therapies with bevacizumab and EGFR-TKIs are a promising strategy to penetrate the blood-brain barrier. Larger trials and prospective studies are warranted.

Research is also being done on the efficacy and tolerability of pulsatile and high-dose EGFR-TKI treatments. A study conducted by Kawamura *et al.* showed that NSCLC patients with refractory CNS metastases responded to high-dose erlotinib (300 mg/d vs. standard dose 150 mg/d) (24). Out of 10 evaluable patients with leptomeningeal metastases, 3 showed MRI response, 4 showed improvement in performance status, and 6 showed an improvement in neurological symptoms (24).

Furthermore, median survival was improved from 5.8 to 6.2 months (24). Jackman *et al.* demonstrated that patients receiving high-dose gefitinib had improvement in neurological symptoms and achieved higher CSF concentrations than with standard dose gefitinib (250 mg/d) (25). They recommended, in areas where clinically available, 750 mg daily for 14 days followed by 500 mg for 15 days in EGFR-mutant positive NSCLC patients with leptomeningeal metastases. Data on high-dose, pulsatile therapy are also promising. A recent case study by Kanemaru *et al.* examined a 64-year-old woman with EGFR-mutant leptomeningeal metastases who had progression of disease on several regimens, including erlotinib and rechallenge with gefitinib. High-dose, pulsatile erlotinib therapy (1,050 mg weekly) was well-tolerated and the patient had improvement in neurological symptoms (26). These data suggest that further research and prospective trials regarding tolerability and efficacy of pulsatile and high-dose EGFR-TKIs may be beneficial in establishing additional treatment regimens for treating EGFR-mutant patients with leptomeningeal metastases.

New EGFR-TKIs that effectively penetrate the blood-brain barrier are also being developed. AZD3759 is a novel EGFR-TKI that has been shown to have 100% CSF penetration. In 29 patients, it was shown to have equal plasma and CSF concentration with no adverse drug-related CNS effects (27). In another study, among five patients with leptomeningeal metastases, four had >50% tumor cell decrease in the CSF and one had complete CSF clearance of tumor cells as well as improvement on brain magnetic resonance imaging (MRI) and CNS symptoms (28). Other adverse effects were similar to that of the existing EGFR-TKIs. These results are reassuring and further clinical study regarding tolerability, dose escalation, comparisons between these novel agents and older EGFR-TKIs is ongoing.

ALK rearrangement

The *ALK* gene encodes the ALK tyrosine kinase receptor. Some of these mutations involve translocation and fusion with the echinoderm microtubule associated protein like 4 (*EML4*) gene and have been identified in patients with NSCLC (29). Leptomeningeal metastases are seen in about 5% of *ALK*-mutant NSCLC patients and take, on average, 9 months to develop (6).

Crizotinib, a first-generation ALK inhibitor, is currently being used as the standard first-line treatment for *ALK*-

rearranged NSCLC. The PROFILE 1007 and 1014 trials found that crizotinib had better outcomes than standard chemotherapy (30,31). Resistance was commonly seen within one to two years of treatment initiation (29). Furthermore, crizotinib showed poor activity against CNS metastases. This may be due to the low blood-brain penetration of most ALK-TKIs, including crizotinib, which has a CSF penetration rate of 0.26% (32). Despite these difficulties, a 2016 study by Johung *et al.* showed that combination therapy with ALK-targeted TKIs and whole-brain radiotherapy had increased survival and PFS (33).

Second-generation ALK inhibitors have been developed in response to the development of resistance to crizotinib. Ceritinib is a second-generation ALK inhibitor that is 20 times more potent than crizotinib and has been studied in patients who have failed crizotinib therapy. Phase I of the ASCEND trial found ceritinib to be highly active and have improved treatment measures in *ALK*-mutated patients who had failed crizotinib therapy (34). These results have been confirmed in the single-arm, open-label, multicenter trials of phase II ASCEND-2 (NCT01685060) and ASCEND-3 (NCT01685138). While the CNS penetration rate of ceritinib and CSF concentrations of ceritinib have not been fully investigated, these trials have had similar CNS and systemic response rates, as well as promising increases in PFS. The currently ongoing ASCEND-7 trial, an open-label, five-arm study, will further determine the efficacy and safety of oral ceritinib in *ALK*-mutant NSCLC patients, including those with leptomeningeal metastases.

Alectinib is another highly-selective ALK inhibitor that has been found to be more potent and effective than crizotinib, and has had a higher CNS response rate than crizotinib (35). Again, CNS penetration rates and CSF concentrations have not been fully studied. However, a multicenter, single-arm, open-label phase I-II study found alectinib to be highly active and well tolerated in patients with advanced, *ALK*-mutant NSCLC (36). Nokihara *et al.* also compared alectinib to both crizotinib and ceritinib and found superior results with alectinib in terms of efficacy and safety in the open-label phase III J-ALEX study (37). Another study examined four *ALK*-rearranged NSCLC patients with leptomeningeal metastases who had failed either crizotinib or ceritinib and found that three had significant clinical and radiological improvements with alectinib and one had stable CNS disease for four months before systemic disease progression (38). Dose escalation after progression of leptomeningeal metastases on standard dosing has also been studied. Gainor *et al.* found that

increasing the dose of alectinib from 600 mg twice a day to 900 mg twice a day resulted in improved clinical and radiological responses (39). This suggests that further study of the dosing of alectinib may be required, specifically to evaluate CNS inhibition and to investigate maintenance of control of disease progression.

Another potent second-generation ALK inhibitor that has been developed is brigatinib. In an ongoing, single-arm, open-label phase I/II study, 137 *ALK*-mutant NSCLC patients who had failed all currently available therapies were evaluated for the efficacy and safety of brigatinib (40). So far, improvement in clinical activity has been encouraging and the safety profile has been within acceptable limits (40). The antitumor activity of this second-generation ALK inhibitor is seen both systemically as well as with brain metastases. More trials are underway, comparing brigatinib to other therapies. For example, the ALTA-1L phase III study is currently recruiting participants to compare the efficacy of brigatinib vs. crizotinib (NCT02737501).

Third-generation ALK inhibitors are currently being developed specifically to optimize CSF penetration. Lorlatinib (PF-06463922) is novel, small molecule ALK and ROS1 inhibitor that has demonstrated effectiveness even in resistant *ALK*-mutant NSCLC. In a phase I/II clinical trials, it has demonstrated a decrease in intracranial symptoms and has even resensitized one patient to crizotinib after failing lorlatinib treatment, indicating that retreatment may be an option (29). Further progressive trials are necessary to evaluate this clinically. Additionally, a phase II trial, currently recruiting patients, is evaluating the safety and efficacy of lorlatinib in *ALK*-positive, advanced NSCLC patients, including those with intracranial disease progression (NCT01970865). Data from these trials will help evaluate whether these novel agents have the potential for treating leptomeningeal metastases that is refractory to currently available therapies.

BRAF and HER2 mutations

BRAF is a proto-oncogene that encodes a component of the mitogen-activated protein kinase (MAPK) pathway. Mutations lead to constitutive kinase activation and ultimately, unregulated cellular growth. These mutations represent approximately 2%–4% of lung cancers (41). The most common *BRAF* mutation in lung cancer is the V600E subtype, which represents about 50% of this population and is the aim of many targeted therapies (41).

A retrospective study of 27 patients showed that vemurafenib, a B-Raf inhibitor, had a 50% intracranial response rate and a 71% extracranial response rate, with one-year overall survival of 30.4% (42). A case study of one patient with metastatic NSCLC also showed improvement in visceral disease and regression of intracranial disease in response to vemurafenib treatment (43). These studies suggest that vemurafenib has sufficient penetration of the blood-brain barrier and may be effective against CNS disease, including leptomeningeal metastases, in those with *BRAF* mutations. Further study is warranted.

The FDA recently granted approval to the combination trametinib and dabrafenib, another B-Raf inhibitor, for treatment in patients with V600E-mutated metastatic melanoma. In a double-blind, placebo-controlled phase 3 trial with 870 patients with resected stage III melanoma, 3-year relapse-free survival was 58% in the combination-therapy group and 39% in the placebo group (95% CI, 0.39–0.58; $P < 0.001$) (44). Additionally, the 3-year overall survival rate and rates of metastasis-free survival were higher in the combination-therapy group (44). Retrospective studies have also shown that in conjunction with radiation therapy, B-Raf inhibitors may improve outcomes (45,46). Further research is needed on the effect of these therapies specifically concerning leptomeningeal metastases. The current research on vemurafenib and recent approval of this combination therapy by the FDA seem to be emerging as promising targeted treatment options for advanced *BRAF*-mutated NSCLC with CNS metastases.

Human epidermal growth factor 2 (*HER2*) mutations, usually associated with breast cancer, are only associated with 2%–5% of lung cancers (47). However, this mutation is associated with an increased incidence of CNS metastases in both breast and lung cancers (48). Trastuzumab is used in *HER2*-positive cancers, but like other monoclonal antibodies they have limited penetration of the blood-brain barrier and are therefore primarily used for control of systemic disease (49). It has been evaluated as an antibody-drug conjugate with the cytotoxic compound, emtastine, in order to increase CNS penetration. In 2015, a retrospective trial showed that trastuzumab-emtastine, also known as T-DM1, was associated with increased overall survival (26.8 months) in those with CNS progression in advanced *HER2*-positive breast cancer compared to capecitabine-lapatinib (50). Additional studies including NSCLC patients with leptomeningeal metastases are necessary to make conclusions about the role of trastuzumab antibody-

drug conjugates such as T-DM1 in this population.

Targeted Immunotherapy

Recent advances have been made in the development of therapies utilizing immunomodulating antibodies against malignant tumors. Programmed cell death protein-1 (PD1) is a cell surface receptor that promotes self-tolerance and have been a target of antibodies in immunotherapy treatment.

A randomized phase III study compared the efficacy of pembrolizumab, an anti-PD1 antibody, against platinum-based chemotherapy in patients with advanced NSCLC. It was shown to be more effective in both overall survival and PFS than platinum-based chemotherapy (51). Additionally, Goldberg *et al.* describes a non-randomized, open-label, ongoing phase II trial that examined pembrolizumab in 18 patients with CNS metastases from NSCLC and found that all but one patient showed ongoing response over the course of one year of treatment (52). While many studies have looked at immunotherapy in systemic treatment, additional studies examining intracranial activity of targeted immunotherapy and studies involving NSCLC patients with advanced leptomeningeal metastases are necessary. More prospective trials will help in determining treatment protocols and safety of immunotherapy in CNS metastases.

Conclusions

Leptomeningeal metastases are a devastating complication, represented in patients with many types of primary cancer including NSCLC, with incidences that may reach up to 20%. Although systemic and targeted therapies are being studied in detail, prognosis remains poor. One of the main obstacles thus far has been the ability for systemic therapy to penetrate the blood-brain barrier to physically reach these metastases. This has become the growing focus of current research in the development of therapies for leptomeningeal and other CNS metastases. Personalized therapies that are precisely designed to penetrate the CSF and target these specific mutations, including *EGFR* and *ALK* variants, have shown increased survival and better safety profiles over non-selective treatment. At this point, further research is warranted to define precise dosages and standard protocols in the treatment for patients with leptomeningeal metastases. With the recent advances in treatment methods, the prognostic outlook of these

metastases is looking more promising.

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

- Demopoulos A. Clinical features and diagnosis of leptomeningeal metastases from solid tumors. Available online: <https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors>
- Mack F, Baumert BG, Schäfer N, et al. Therapy of leptomeningeal metastasis in solid tumors. *Cancer Treat Rev* 2016;43:83-91.
- Demopoulos A, Brown P. Treatment of leptomeningeal metastases (carcinomatous meningitis). Available online: <https://www.uptodate.com/contents/treatment-of-leptomeningeal-metastases-carcinomatous-meningitis>
- Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French cooperative thoracic intergroup (IFCT). *Lancet* 2016;387:1415-26.
- Yufen X, Binbin S, Wenyu C, et al. The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer. *Springerplus* 2016;5:1244.
- Remon J, Le Rhun E, Besse B. Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era. *Cancer Treat Rev* 2017;53:128-137.
- Wu JY, Wu SG, Yang CH, et al. Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations. *Lung Cancer* 2011;72:205-12.
- Yang H, Yang X, Zhang Y, et al. Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib failure. *Target Oncol* 2015;10:135-40.
- Yuan Y, Tan C, Li M, et al. Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib. *World J Surg Oncol* 2012;10:235.
- Masuda T, Hattori N, Hamada A, et al. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. *Cancer Chemother Pharmacol* 2011;67:1465-9.
- Togashi Y, Masago K, Hamatani Y, et al. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature. *Lung Cancer* 2012;77:464-8.
- Togashi Y, Masago K, Masuda S, et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. *Cancer Chemother Pharmacol* 2012;70:399-405.
- Lee E, Keam B, Kim DW, et al. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. *J Thorac Oncol* 2013;8:1069-74.
- Hoffknecht P, Tufman A, Wehler T, et al. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. *J Thorac Oncol* 2015;10:156-63.
- Remon J, Le Rhun E, Besse B. Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era. *Cancer Treat Rev* 2017;53:128-37.
- Ballard P, Yates JW, Yang Z, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. *Clin Cancer Res* 2016;22:5130-40.
- Nanjo S, Ebi H, Arai S, et al. High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells. *Oncotarget* 2016;7:3847-56.
- Yang JCH, Cho CB, Kim DW, et al. Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer

- (NSCLC): Updated results from the BLOOM study. *J Clin Oncol* 2017;35:15_suppl, 2020-2020.
19. Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. *N Engl J Med* 2017;376:629-40.
 20. Ariyasu R, Horiike A, Koyama J, et al. Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib. *Anticancer Drugs* 2017;28:565-7.
 21. Sakata Y, Kawamura K, Shingu N, et al. Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer. *Lung Cancer* 2016;99:120-2.
 22. Furugaki K, Fukumura J, Iwai T, et al. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification. *Int J Cancer* 2016;138:1024-32.
 23. Ichihara E, Hotta K, Nogami N, et al. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating *EGFR* gene mutations: the Okayama Lung Cancer Study Group Trial 1001. *J Thorac Oncol* 2015;10:486-91.
 24. Kawamura T, Hata A, Takeshita J, et al. High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs. *Cancer Chemother Pharmacol* 2015;75:1261-6.
 25. Jackman DM, Cioffredi LA, Jacobs L, et al. A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. *Oncotarget* 2015;6:4527-36.
 26. Kanemaru R, Morio Y, Takekawa H, et al. Successful treatment with weekly high-dose erlotinib against meningeal metastases from epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma. *Respir Investig* 2016;54:372-5.
 27. Tan CS, Cho BC, Soo RA. Treatment options for EGFR mutant NSCLC with CNS involvement — Can patients BLOOM with the use of next generation EGFR TKIs? *Lung Cancer* 2017;108:29-37.
 28. Ahn MJ, Kim DW, Kim TM, et al. Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastases (BM) and leptomeningeal metastases (LM). *J Clin Oncol* 2016;34:15_suppl, 9003-9003.
 29. Wu J, Savooji J, Liu D. Second- and third-generation ALK inhibitors for non-small cell lung cancer. *J Hematol Oncol* 2016;9:19.
 30. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med* 2013;368:2385-94.
 31. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med* 2014;371:2167-77.
 32. Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. *J Clin Oncol* 2011;29:e443-5.
 33. Johung KL, Yeh N, Desai NB, et al. Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. *J Clin Oncol* 2016;34:123-9.
 34. Shaw AT, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. *N Engl J Med* 2014;370:2537-9.
 35. Qian M, Zhu B, Wang X, et al. Drug resistance in ALK-positive Non-small cell lung cancer patients. *Semin Cell Dev Biol* 2017;64:150-7.
 36. Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): A single-arm, open-label, phase 1-2 study. *Lancet Oncol* 2013;14:590-8.
 37. Nokihara H, Hida T, Kondo M. Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive *ALK*-positive non-small cell lung cancer (*ALK*+NSCLC): Primary results from the J-ALEX study. *J Clin Oncol* 2016;34.
 38. Gainor JF, Sherman CA, Willoughby K, et al. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. *J Thorac Oncol* 2015;10:232-6.
 39. Gainor JF, Chi AS, Logan J, et al. Alectinib dose escalation reinduces central nervous system responses in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer relapsing on standard dose alectinib. *J Thorac Oncol* 2016;11:256-60.
 40. Gettinger SN, Bazhenova LA, Langer CJ, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: A

- single-arm, open-label, phase 1/2 trial. *Lancet Oncol* 2016;17:1683-96.
41. Nguyen-Ngoc T, Bouchaab H, Adjei AA, et al. BRAF alterations as therapeutic targets in non-small-cell lung cancer. *J Thorac Oncol* 2015;10:1396-403.
 42. Harding JJ, Catalanotti F, Munhoz RR, et al. A retrospective evaluation of vemurafenib as treatment for BRAF-mutant melanoma brain metastases. *Oncologist* 2015;20:789-97.
 43. Robinson SD, O'Shaughnessy JA, Cowey CL, et al. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. *Lung Cancer* 2014;85:326-30.
 44. Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. *N Eng J Med* 2017;377:1813-23.
 45. Xu Z, Lee CC, Ramesh A, et al. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases. *J Neurosurg* 2017;126:726-34.
 46. Patel KR, Chowdhary M, Switchenko JM, et al. BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. *Melanoma Res* 2016;26:387-94.
 47. Takase Y, Usui K, Shimizu K, et al. Highly sensitive detection of a HER2 12-base pair duplicated insertion mutation in lung cancer using the Eprobe-PCR method. *PLoS One* 2017;12:e0171225.
 48. Garrido-Castro AC, Felip E. HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches. *Transl Lung Cancer Res* 2013;2:122-7.
 49. Venur VA, Leone JP. Targeted therapies for brain metastases from breast cancer. *Int J Mol Sci* 2016;17.
 50. Krop IE, Lin NU, Blackwell K, et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: A retrospective, exploratory analysis in EMILIA. *Ann Oncol* 2015;26:113-9.
 51. Addeo R. A new frontier for targeted therapy in NSCLC: Clinical efficacy of pembrolizumab in the inhibition of programmed cell death 1 (PD-1). *Expert Rev Anticancer Ther* 2017;17:199-201.
 52. Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. *Lancet Oncol* 2016;98:114-7.

Cite this article as: Shah BK, Pak I, Budhathoki N, Buker K. Targeted therapy for leptomeningeal metastases in non-small cell lung cancer – Changing treatment paradigms. *Chin J Cancer Res* 2017;29(6):535-542. doi: 10.21147/j.issn.1000-9604.2017.06.08